{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:57:18Z","timestamp":1761919038647},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,11,21]],"date-time":"2007-11-21T00:00:00Z","timestamp":1195603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2003<\/jats:bold> Photodynamic therapy (PDT) is an accepted treatment for superficial basal cel carcinoma (sBCC) and Bowens disease. In Rotterdam, extensive preclinical research has lead to an optimized twofold illumination scheme for aminolevulinic acid\u2013PDT (ALA\u2010PDT).<\/jats:p><jats:p><jats:bold>Objective\u2003<\/jats:bold> To provide additional evidence of ALA\u2010PDT for sBCC, Bowens disease (BD), nodular BCC (nBCC) and actinic keratosis (AK) using a 2\u2010fold illumination scheme after a single application of ALA.<\/jats:p><jats:p><jats:bold>Methods\u2003<\/jats:bold> Five hundred fifty\u2010two lesions (430 sBCC, 20 nBCC, 32 BD, 70 AK) were treated with ALA\u2010PDT using a twofold illumination scheme. ALA was applied topically for 4\u00a0h. Lesions were treated with two light fractions of 20 and 80\u00a0J\/cm<jats:sup>2<\/jats:sup> separated by a 2\u2010h dark interval.<\/jats:p><jats:p><jats:bold>Results\u2003<\/jats:bold> After a minimum follow\u2010up of 12\u00a0months, in average follow\u2010up of 2\u00a0years, an overall complete response of 95% was seen for all lesions. For sBCC, the complete response at 2 years was 97% (for AK 98%, for BD 84% and for nBCC 80% after 2\u00a0years). A sub\u2010analysis of the results of lesions larger than 2\u00a0cm showed CR at 2 years of 89% for all lesions (<jats:italic>n<\/jats:italic>\u00a0=\u00a057). Cosmetic outcome was good to excellent in 95% of the treated lesions.<\/jats:p><jats:p><jats:bold>Conclusion\u2003<\/jats:bold> ALA\u2010PDT using a twofold illumination scheme of 20 plus 80\u00a0J\/cm<jats:sup>2<\/jats:sup> separated by a 2\u2010h dark interval leads to high complete response rates at 2 years and can be regarded as an evidence\u2010based treatment modality for superficial growing non\u2010melanoma skin cancer and the (pre)malignant AK. The Rotterdam fractionated approach should be included in future guidelines.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2007.02445.x","type":"journal-article","created":{"date-parts":[[2007,11,21]],"date-time":"2007-11-21T19:37:19Z","timestamp":1195673839000},"page":"426-430","source":"Crossref","is-referenced-by-count":59,"title":["Fractionated aminolevulinic acid\u2013photodynamic therapy provides additional evidence for the use of PDT for non\u2010melanoma skin cancer"],"prefix":"10.1111","volume":"22","author":[{"given":"ERM","family":"De Haas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HC","family":"De Vijlder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HJCM","family":"Sterenborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAM","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DJ","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,11,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.006"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/1011-1344(90)85083-9"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04719.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0129"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700460"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.264"},{"key":"e_1_2_6_8_2","unstructured":"Dutch Cancer Society Grants(KWF) DDHK\u20101686 DDHK\u20101881 and EMCR 2718.RobinsonDJ SluiterW NeumannHAM.Investigating the mechanism of the increase in damage during ALA\u2010PDT achieved using a long term light fractionation scheme.20022006."},{"key":"e_1_2_6_9_2","first-page":"901","article-title":"Improvement of systemic 5\u2010aminolevulinic acid photodynamic therapy in\u2010vivo using light fractionation with a 75\u2010minute interval","volume":"59","author":"De Bruijn HS","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1562\/0031-8655(2000)0720794TAAPTO2.0.CO2"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1562\/0031-8655(2003)0770319DATOTF2.0.CO2"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1998.tb05177.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2006.07.004"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","unstructured":"De BruijnHS De HaasERM HebedaKMet\u00a0al.Light fractionation does not enhance the efficacy of Methyl 5\u2010aminolevulinate mediated photodynamic therpay in normal mouse skin.Photochem Photobiol2007; in press.","DOI":"10.1039\/b708340h"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2001.04407.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.1.17"},{"key":"e_1_2_6_17_2","first-page":"642","article-title":"Similar effectiveness of methyl aminolevulinate and 5\u2010aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma","volume":"5","author":"Kuijpers DI","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_18_2","first-page":"462","article-title":"New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma)","volume":"4","author":"Cockerel CJ","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/qhc.12.1.18"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/15.1.31"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","unstructured":"De HaasERM De VijderHC Siewertsz van ReesemaW Van EverdingenJJE NeumannHAM.Quality of clinical practice guidelines in dermatological oncology.J Eur Acad Dermatol Venereol2007. doi:10.1111\/j.1468-3083.2007.02216.x","DOI":"10.1111\/j.1468-3083.2007.02216.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2007.02445.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2007.02445.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T15:17:36Z","timestamp":1697037456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2007.02445.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,21]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1468-3083.2007.02445.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2007.02445.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,21]]}}}